Global Biologic Drugs Market Research Report 2019 by Manufacturers, Regions, Types and Applications
Table of Contents
1 Executive Summary
- 1.1 Definition and Specification
- 1.2 Report Overview
- 1.2.1 Manufacturers Overview
- 1.2.2 Regions Overview
- 1.2.3 Type Overview
- 1.2.4 Application Overview
- 1.3 Industrial Chain
- 1.3.1 Biologic Drugs Overall Industrial Chain
- 1.3.2 Upstream
- 1.3.3 Downstream
- 1.4 Industry Situation
- 1.4.1 Industrial Policy
- 1.4.2 Product Preference
- 1.4.3 Economic/Political Environment
- 1.5 SWOT Analysis
2 Market Analysis by Types
- 2.1 Overall Market Performance(Volume)
- 2.1.1 Humira
- 2.1.2 Remicade
- 2.1.3 Rituxan
- 2.1.4 Enbrel
- 2.1.5 Lantus
- 2.1.6 Avastin
- 2.1.7 Herceptin
- 2.1.8 Others
- 2.2 Overall Market Performance(Value)
- 2.2.1 Humira
- 2.2.2 Remicade
- 2.2.3 Rituxan
- 2.2.4 Enbrel
- 2.2.5 Lantus
- 2.2.6 Avastin
- 2.2.7 Herceptin
- 2.2.8 Others
3 Product Application Market
- 3.1 Overall Market Performance (Volume)
- 3.1.1 Diabetes
- 3.1.2 Inflammation
- 3.1.3 Auto-Immune Diseases
- 3.1.4 Blood Diseases
- 3.1.5 Cardiovascular Diseases
- 3.1.6 Others
4 Manufacturers Profiles/Analysis
- 4.1 Roche
- 4.1.1 Roche Profiles
- 4.1.2 Roche Product Information
- 4.1.3 Roche Biologic Drugs Sales, Sales Value(Million USD), Price and Gross Profit
- 4.1.4 Roche SWOT Analysis
- 4.2 Abbott Laboratories
- 4.2.1 Abbott Laboratories Profiles
- 4.2.2 Abbott Laboratories Product Information
- 4.2.3 Abbott Laboratories Biologic DrugsSales, Sales Value (Million USD), Price and Gross Profit
- 4.2.4 Abbott Laboratories SWOT Analysis
- 4.3 Johnson & Johnson
- 4.3.1 Johnson & Johnson Profiles
- 4.3.2 Johnson & Johnson Product Information
- 4.3.3 Johnson & Johnson Biologic DrugsSales, Sales Value (Million USD), Price and Gross Profit
- 4.3.4 Johnson & Johnson SWOT Analysis
- 4.4 Merck & Co.
- 4.4.1 Merck & Co. Profiles
- 4.4.2 Merck & Co. Product Information
- 4.4.3 Merck & Co. Biologic DrugsSales, Sales Value (Million USD), Price and Gross Profit
- 4.4.4 Merck & Co. SWOT Analysis
- 4.5 Pfizer
- 4.5.1 Pfizer Profiles
- 4.5.2 Pfizer Product Information
- 4.5.3 Pfizer Biologic DrugsSales, Sales Value (Million USD), Price and Gross Profit
- 4.5.4 Pfizer SWOT Analysis
- 4.6 Amgen
- 4.6.1 Amgen Profiles
- 4.6.2 Amgen Product Information
- 4.6.3 Amgen Biologic DrugsSales, Sales Value (Million USD), Price and Gross Profit
- 4.6.4 Amgen SWOT Analysis
- 4.7 Sanofi
- 4.7.1 Sanofi Profiles
- 4.7.2 Sanofi Product Information
- 4.7.3 Sanofi Biologic DrugsSales, Sales Value (Million USD), Price and Gross Profit
- 4.7.4 Sanofi SWOT Analysis
- 4.8 Novartis
- 4.8.1 Novartis Profiles
- 4.8.2 Novartis Product Information
- 4.8.3 Novartis Biologic DrugsSales, Sales Value (Million USD), Price and Gross Profit
- 4.8.4 Novartis SWOT Analysis
- 4.9 Eli Lilly
- 4.9.1 Eli Lilly Profiles
- 4.9.2 Eli Lilly Product Information
- 4.9.3 Eli Lilly Biologic DrugsSales, Sales Value (Million USD), Price and Gross Profit
- 4.9.4 Eli Lilly SWOT Analysis
- 4.10 Amgen
- 4.10.1 Amgen Profiles
- 4.10.2 Amgen Product Information
- 4.10.3 Amgen Biologic DrugsSales, Sales Value (Million USD), Price and Gross Profit
- 4.10.4 Amgen SWOT Analysis
5 Market Performance for Manufacturers
- 5.1 Global Biologic Drugs Sales (K Units) and Market Share by Manufacturers 2014-2020
- 5.2 Global Biologic Drugs Revenue (M USD) and Market Share by Manufacturers 2014-2020
- 5.3 Global Biologic Drugs Price (USD/Unit) of Manufacturers 2014-2020
- 5.4 Global Biologic Drugs Gross Margin of Manufacturers 2014-2020
- 5.5 Market Concentration
6 Regions Market Performance for Manufacturers
- 6.1 China Market Performance for Manufacturers
- 6.1.1 China Biologic Drugs Sales (K Units) and Share of Manufacturers 2014-2020
- 6.1.2 China Biologic Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
- 6.1.3 China Biologic Drugs Price (USD/Unit) of Manufacturers 2014-2020
- 6.1.4 China Biologic Drugs Gross Margin of Manufacturers 2014-2020
- 6.1.5 Market Concentration
- 6.2 USA Market Performance for Manufacturers
- 6.2.1 USA Biologic Drugs Sales (K Units) and Share of Manufacturers 2014-2020
- 6.2.2 USA Biologic Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
- 6.2.3 USA Biologic Drugs Price (USD/Unit) of Manufacturers 2014-2020
- 6.2.4 USA Biologic Drugs Gross Margin of Manufacturers 2014-2020
- 6.2.5 Market Concentration
- 6.3 Europe Market Performance for Manufacturers
- 6.3.1 Europe Biologic Drugs Sales (K Units) and Share of Manufacturers 2014-2020
- 6.3.2 Europe Biologic Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
- 6.3.3 Europe Biologic Drugs Price (USD/Unit) of Manufacturers 2014-2020
- 6.3.4 Europe Biologic Drugs Gross Margin of Manufacturers 2014-2020
- 6.3.5 Market Concentration
- 6.4 Japan Market Performance for Manufacturers
- 6.4.1 Japan Biologic Drugs Sales (K Units) and Share of Manufacturers 2014-2020
- 6.4.2 Japan Biologic Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
- 6.4.3 Japan Biologic Drugs Price (USD/Unit) of Manufacturers 2014-2020
- 6.4.4 Japan Biologic Drugs Gross Margin of Manufacturers 2014-2020
- 6.4.5 Market Concentration
- 6.5 Korea Market Performance for Manufacturers
- 6.5.1 Korea Biologic Drugs Sales (K Units) and Share of Manufacturers 2014-2020
- 6.5.2 Korea Biologic Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
- 6.5.3 Korea Biologic Drugs Price (USD/Unit) of Manufacturers 2014-2020
- 6.5.4 Korea Biologic Drugs Gross Margin of Manufacturers 2014-2020
- 6.5.5 Market Concentration
- 6.6 India Market Performance for Manufacturers
- 6.6.1 India Biologic Drugs Sales (K Units) and Share of Manufacturers 2014-2020
- 6.6.2 India Biologic Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
- 6.6.3 India Biologic Drugs Price (USD/Unit) of Manufacturers 2014-2020
- 6.6.4 India Biologic Drugs Gross Margin of Manufacturers 2014-2020
- 6.6.5 Market Concentration
- 6.7 Southeast Asia Market Performance for Manufacturers
- 6.7.1 Southeast Asia Biologic Drugs Sales (K Units) and Share of Manufacturers 2014-2020
- 6.7.2 Southeast Asia Biologic Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
- 6.7.3 Southeast Asia Biologic Drugs Price (USD/Unit) of Manufacturers 2014-2020
- 6.7.4 Southeast Asia Biologic Drugs Gross Margin of Manufacturers 2014-2020
- 6.7.5 Market Concentration
- 6.8 South America Market Performance for Manufacturers
- 6.8.1 South America Biologic Drugs Sales (K Units) and Share of Manufacturers 2014-2020
- 6.8.2 South America Biologic Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
- 6.8.3 South America Biologic Drugs Price (USD/Unit) of Manufacturers 2014-2020
- 6.8.4 South America Biologic Drugs Gross Margin of Manufacturers 2014-2020
- 6.8.5 Market Concentration
7 Global Biologic Drugs Market Assessment by Regions (2014-2020)
- 7.1 Global Biologic Drugs Sales (K Units) and Market Share by Regions 2014-2020
- 7.2 Global Biologic Drugs Revenue (M USD) and Market Share by Regions 2014-2020
- 7.3 Global Biologic Drugs Price (USD/Unit) by Regions 2014-2020
- 7.4 Global Biologic Drugs Gross Margin by Regions 2014-2020
8 Development Trend for Regions
- 8.1 Global Biologic Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
- 8.2 China Biologic Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
- 8.3 USA Biologic Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
- 8.4 Europe Biologic Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
- 8.5 Japan Biologic Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
- 8.6 Korea Biologic Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
- 8.7 India Biologic Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
- 8.8 Southeast Asia Biologic Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
- 8.8 Southeast Asia Biologic Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
9 Upstream Source, Technology and Cost
- 9.1 Upstream Source
- 9.2 Technology
- 9.3 Cost
10 Channel Analysis
- 10.1 Market Channel
- 10.2 Manufacturing Plants Distribution
11 Consumer Analysis
- 11.1 Diabetes Industry
- 11.2 Inflammation Industry
- 11.3 Auto-Immune Diseases Industry
- 11.4 Blood Diseases Industry
- 11.5 Cardiovascular Diseases Industry
- 11.6 Others Industry
12 Market Forecast 2021-2026
- 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2021-2026
- 12.1.1 Global Biologic Drugs Sales (K Units), Revenue (M USD) and Market Share by Regions 2021-2026
- 12.1.2 Global Biologic Drugs Sales (K Units) and Growth Rate 2021-2026
- 12.1.3 China Biologic Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
- 12.1.4 USA Biologic Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
- 12.1.5 Europe Biologic Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
- 12.1.6 Japan Biologic Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
- 12.1.7 Korea Biologic Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
- 12.1.8 India Biologic Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
- 12.1.9 Southeast Asia Biologic Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
- 12.1.10 South America Biologic Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
- 12.2 Sales (K Units), Revenue (M USD) Forecast by Types 2021-2026
- 12.2.1 Overall Market Performance
- 12.2.2 Humira
- 12.2.3 Remicade
- 12.2.4 Rituxan
- 12.2.5 Enbrel
- 12.2.6 Lantus
- 12.2.7 Avastin
- 12.2.8 Herceptin
- 12.2.9 Others
- 12.3 Sales (K Units) Forecast by Application 2021-2026
- 12.3.1 Overall Market Performance
- 12.3.2 Diabetes
- 12.3.3 Inflammation
- 12.3.4 Auto-Immune Diseases
- 12.3.5 Blood Diseases
- 12.3.6 Cardiovascular Diseases
- 12.3.7 Others
- 12.4 Price (USD/Unit) and Gross Profit
- 12.4.1 Global Biologic Drugs Price (USD/Unit) Trend 2021-2026
- 12.4.2 Global Biologic Drugs Gross Profit Trend 2021-2026
13 Conclusion
According to XYZResearch study, over the next five years the Biologic Drugsmarket will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026, from US$ xx million in 2020. In particular, this report presents the global market share (sales and revenue) of key companies in Biologic Drugsbusiness.
Biologic Drugs market development trend, sales volume and sales value (million USD) forecast in regional market, the main regions are China, USA, Europe, India, Japan, Korea, South America, Southeast Asia.
Sales forecast by type/application from 2021-2026
Industry chain, downstream and upstream information is also included.
World trade was already slowing in 2019 before COVID 19 outbreak, weighed down by trade tensions and slowing economic growth, such as uncertainty generated from Brexit, the U.S.-China trade war, the Japan-South Korea trade war.
Trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world, according to the study of WTO. The decline in exports has been mainly due to the ongoing global slowdown, which got aggravated due to the current Covid-19 crisis. The latter resulted in large scale disruptions in supply chains and demand resulting in cancellation of orders.
XYZResearch’s analysis shows that as China started reopening its economy, world exports initially recovered across the board. But estimates of the expected recovery in 2021 are uncertain, with outcomes depending largely on the duration of the outbreak and the effectiveness of the policy responses.
This report split global into several key Regions, with sales (K Units), revenue (M USD), market share and growth rate of Biologic Drugs for these regions, from 2014 to 2026 (forecast), covering
China
USA
Europe
Japan
Korea
India
Southeast Asia
South America
Global Biologic Drugs market competition by top manufacturers/players, with Biologic Drugs sales volume, Price (USD/Unit), revenue (M USD) and market share for each manufacturer/player; the top players including
Roche
Abbott Laboratories
Johnson & Johnson
Merck & Co.
Pfizer
Amgen
Sanofi
Novartis
Eli Lilly
Amgen
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Humira
Remicade
Rituxan
Enbrel
Lantus
Avastin
Herceptin
Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Biologic Drugs for each application, including
Diabetes
Inflammation
Auto-Immune Diseases
Blood Diseases
Cardiovascular Diseases
Others
Feel free to let me know if you have any special requirements.